TY  - JOUR
AU  - Tomsitz, Dirk
AU  - Ruf, Theresa
AU  - Heppt, Markus
AU  - Staeger, Ramon
AU  - Ramelyte, Egle
AU  - Dummer, Reinhard
AU  - Garzarolli, Marlene
AU  - Meier, Friedegund
AU  - Meier, Eileen
AU  - Richly, Heike
AU  - Gromke, Tanja
AU  - Siveke, Jens
AU  - Franklin, Cindy
AU  - Klespe, Kai-Christian
AU  - Mauch, Cornelia
AU  - Kilian, Teresa
AU  - Seegräber, Marlene
AU  - Schilling, Bastian
AU  - French, Lars E.
AU  - Berking, Carola
AU  - Heinzerling, Lucie
TI  - Tebentafusp in Patients with Metastatic Uveal Melanoma: A Real-Life Retrospective Multicenter Study
JO  - Cancers
VL  - 15
IS  - 13
SN  - 2072-6694
CY  - Basel
PB  - MDPI
M1  - DKFZ-2023-01436
SP  - 3430
PY  - 2023
AB  - Background: Tebentafusp has recently been approved for the treatment of metastatic uveal melanoma (mUM) after proving to have survival benefits in a first-line setting.Patients and methods: This retrospective, multicenter study analyzed the outcomes and safety of tebentafusp therapy in 78 patients with mUM.Results: Patients treated with tebentafusp had a median PFS of 3 months (95
LB  - PUB:(DE-HGF)16
C6  - pmid:37444540
DO  - DOI:10.3390/cancers15133430
UR  - https://inrepo02.dkfz.de/record/277719
ER  -